Phio Pharmaceuticals Corp (PHIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has a cash flow conversion efficiency ratio of -0.243x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.00 Million) by net assets ($16.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PHIO company net worth for the company's overall valuation and market capitalisation.
Phio Pharmaceuticals Corp - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Phio Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Phio Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their cash flow conversion efficiency. See debt repayment capacity of Phio Pharmaceuticals Corp to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
S F Capital Bhd
KLSE:8745
|
-0.131x |
|
Volcano Bhd
KLSE:0232
|
0.027x |
|
Xelpmoc Design And Tech Limited
NSE:XELPMOC
|
-0.051x |
|
Natural Alternatives International
NASDAQ:NAII
|
-0.094x |
|
5G Networks Ltd
AU:5GN
|
-0.146x |
|
Sanko Diecasting (Thailand) Public Company Limited
BK:SANKO
|
0.092x |
|
Basel Medical Group Ltd Ordinary Shares
NASDAQ:BMGL
|
N/A |
|
Value8 N.V
AS:PREVA
|
0.000x |
Annual Cash Flow Conversion Efficiency for Phio Pharmaceuticals Corp (2011–2025)
The table below shows the annual cash flow conversion efficiency of Phio Pharmaceuticals Corp from 2011 to 2025. View latest Phio Pharmaceuticals Corp stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.15 Million | $-7.98 Million | -0.396x | +73.70% |
| 2024-12-31 | $4.72 Million | $-7.11 Million | -1.506x | -8.29% |
| 2023-12-31 | $7.73 Million | $-10.75 Million | -1.391x | -24.28% |
| 2022-12-31 | $10.84 Million | $-12.13 Million | -1.119x | -106.95% |
| 2021-12-31 | $21.93 Million | $-11.86 Million | -0.541x | +20.04% |
| 2020-12-31 | $13.02 Million | $-8.80 Million | -0.676x | +55.04% |
| 2019-12-31 | $5.75 Million | $-8.64 Million | -1.504x | -171.56% |
| 2018-12-31 | $13.58 Million | $-7.52 Million | -0.554x | +89.33% |
| 2017-12-31 | $1.83 Million | $-9.51 Million | -5.190x | -626.05% |
| 2016-12-31 | $10.86 Million | $-7.76 Million | -0.715x | +13.14% |
| 2015-12-31 | $8.89 Million | $-7.32 Million | -0.823x | +70.88% |
| 2014-12-31 | $2.75 Million | $-7.76 Million | -2.826x | -121.32% |
| 2013-12-31 | $4.94 Million | $-6.31 Million | -1.277x | -247.33% |
| 2012-12-31 | $-5.84 Million | $-5.06 Million | 0.867x | -94.91% |
| 2011-12-31 | $-587.00K | $-9.99 Million | 17.017x | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more